Fatty Liver Alliance’s Post

Drs. Mark Swain (Hepatologist), Kenneth Cusi/Kenny Cusi (Endocrinologist), Hsiao-Ming Jung (Primary Care) and Michael Betel (President and Founder of Fatty Liver Alliance) have a very engaging and informative discussion about referral and collaboration in this panel discussion from the NAFLD and NASH Primary Care Summit. A multi-disciplinary team is critical now more than ever, for patients who have MASLD and MASH. What are the Indications for referral to a specialist? What is the importance of interdisciplinary collaboration for optimal patient care? In this 'Referral and Collaboration Panel Discussion' experts emphasized the importance of a multi-disciplinary approach for managing MASLD and MASH patients. Dr. Mark Swain, President of Canadian Association for the Study of the Liver, and his colleagues highlighted the need for collaborative care with the patient at the center, recognizing the complexity of cases involving multiple comorbidities. They stressed the necessity of a team approach for a holistic and effective treatment strategy. Key points discussed include the need for primary care physicians to seek specialist assistance, the significance of interdisciplinary collaboration, and the importance of early diagnosis and treatment. The panel also touched on public health issues, the accessibility of treatments like the GLP-1 drug, and dietary challenges. A major takeaway for primary care providers is the use of FIB-4 for assessing liver disease risk, enabling a comprehensive and focused approach to patient care. Canadian Nurses Association, European Association for the Study of Obesity (EASO), EASL | The Home of Hepatology, American Association for the Study of Liver Diseases (AASLD), European Liver Patients' Association - ELPA, Global Liver Institute, Mark Donnison, EMBA, Philippe Garneau, Supriya Joshi, Cheryl Dale RN(EC) MScN AF-AASLD, The College of Family Physicians of Canada

Here is a MASLD (NAFLD/fatty liver disease) case study you have to watch! Professor Manal Abdelmalek, Hepatologist does a brilliant job presenting a case to her interdisciplinary colleagues. The discussion is incredible, as are the insights you will gain. Join Professor Kenneth Cusi, Endocrinologist (Kenny Cusi),and Dr. Joshua Juan, Primary Care Physician, as they discuss the case of a patient, Jorge, 55 years old who has multiple co-morbidities, including Type-2 Diabetes, Hypertension, obesity and Hyperlipidemia, who currently is feeling well. Dr. Alnoor Ramji, Hepatologist moderates and patient Kerry Sivia joins in for the Q & A. 1. Multidisciplinary Approach: The discussion emphasized the importance of a team approach involving primary care, endocrinology, hepatology, and nutrition to manage complex patient cases like Jorge's. It highlighted the need for comprehensive care beyond a single specialty to address the multifaceted aspects of metabolic syndrome and related complications. 2. Importance of Lifestyle Modifications and Patient Motivation: Despite medical interventions, the significance of lifestyle changes was underscored, alongside the challenge of motivating patients. Strategies to motivate patients, such as focusing on family, quality of life, and leveraging a patient's personal values and goals, were discussed as critical for managing chronic conditions effectively. 3. Role of Advanced Diagnostic and Monitoring Tools: The conversation highlighted the utility of diagnostic tools like FibroScan and the importance of monitoring biomarkers such as hemoglobin A1c, liver enzymes, and fibrosis scores. It stressed that these tools should guide clinical decisions, including when to escalate care to specialists or consider treatments like bariatric surgery or clinical trials for advanced therapies. 4. Complexity of Managing Comorbid Conditions: The case illustrated the complexity of managing comorbid conditions such as diabetes, obesity, and Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), stressing the need for careful consideration of medication choices, potential side effects, and interactions. The discussion pointed out the challenges in balancing glucose control with the risk of weight gain and the potential for liver disease progression. 5. Preventative Care and Early Intervention: Finally, the importance of preventative care and early intervention was highlighted, emphasizing the need for regular monitoring, early referral to specialists when necessary, and consideration of patient history and risk factors for more severe conditions like cirrhosis and cardiovascular disease. Canadian Association for the Study of the Liver, Canadian Association of Hepatology Nurses, American Association for the Study of Liver Diseases (AASLD), European Liver Patients' Association - ELPA, EASL | The Home of Hepatology, MCI, Global Liver Institute, Canadian Family Physician, The The College of Family Physicians of Canada  #masld

Global estimates of fatty liver disease (MASLD) exceed 38%, and this epidemic needs to be addressed with urgency. Jeffrey V. Lazarus et al., in this article, 'Turning the Tide on MASLD and MASH' (published in Hepatology), discuss an action plan to address this global epidemic. It won't be easy, but we need to work together and we need to start now. "Critically, implementing these actions will require a fundamental shift in the liver field from a narrow focus on hepatology to a more comprehensive approach that includes various stakeholders from different medical specializations, such as endocrinology, primary care, and cardiology, alongside public health experts, social scientists, policymakers and governments, pharmaceutical and device industries, patient advocates, and, most importantly, patients themselves." The top calls to action, based on their relevance to improving patient care and outcomes, include: * Collaboration between liver specialists and primary care * Addressing the needs of people with multiple morbidities * Incorporating fatty liver disease into existing NCD strategies and guidelines * Developing and implementing patient-centered models of care * Enhancing education and awareness * Promoting standardization of data collection * Implementing community-tailored models of care * Developing tools * Advocating for and establishing a global coalition * Engaging with health system decision-makers EASL | The Home of Hepatology, Canadian Association for the Study of the Liver, American Association for the Study of Liver Diseases (AASLD), Canadian Association of Hepatology Nurses, European Liver Patients' Association - ELPA #liverhealth #masld #mash Alina M. Allen, Zobair Younossi, Aleksander Krag, Juan Pablo Arab, Quentin M. Anstee, Sven Francque, Naim Alkhouri, Mazen Noureddin, MD, MHSc, Christopher Kopka, Philip Newsome, Maru/Mary Rinella, Prof. Shira Zelber Sagi, Jörn M. Schattenberg, Diana Romero, Vincent Wong, marcelo silva Original paper: Hepatology 79(2):p 502-523, February 2024. | https://lnkd.in/g7pXzfF5

New Research from the National Kidney Foundation Spring Clinical Meetings: a new study compares chlorthalidone and hydrochlorothiazide in over 12,000 participants. Learn more by reading the National Kidney Foundation’s most recent bog: https://bit.ly/4bVsyDj #MedicalResearch #NKFofAZ #KidneyDisease #KidneyStrong #KidneyHealth #KidneyResearch

Once again, research highlights the importance of psychoeducation in health care and adherence to medical treatments. A multidisciplinary intervention can make a difference in both short and long-term outcomes, and definitely can save lifes. Check out this important article from National Kidney Foundation

Genetic studies are essential for the early and correct diagnosis of rare diseases.

Invizius has recently announced the latest update from its first-in-human trial for their novel priming solution, H-Guard, sharing that eight patients have been successfully treated at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF). To learn more about H-Guard and the successful trial, follow the link below to read the full article!

In collaboration with other funders, this is the difference supporters of Crohn's & Colitis UK make. This is IMPACT. This is WHY we do what we do. This is why investing in medical research is so vitally important. For Billie and for everyone living with IBD. https://lnkd.in/e4KBKfAu

See this new interview with past About IBD Podcast guest and IBD specialist Dr Gaidos!

🚨 Calling all researchers and pharmacists! We have two grant rounds opening today, Tuesday 4 June, for UK-based applicants. 1) Funding call for research into Alport syndrome In partnership with the Stoneygate Trust, we have established a UK hub dedicated to the study and treatment of Alport syndrome. The hub aims to accelerate research, transform early diagnosis, and develop specific treatments for the disease. We are looking for researchers who can transform Alport syndrome. For more information, click here: https://bit.ly/3PG99OQ 2) Pharmacy-led research and research into nephrotoxicity For the first time we are leading a collaborative drive to develop and enhance pharmacy-led research and pharmacy-related research in partnership with Pharmacy Research UK, The UK Kidney Association’s Renal Pharmacy Group, The Paediatric Medicines Research Unit, Alder Hey Children’s Hospital and the Thompson Family Trust. With a specific focus on nephrotoxicity, we want to help our understanding and prevent deterioration of kidney function due to toxic effects of medications and chemicals. In this funding call, we are looking for researchers with an interest in nephrotoxicity, and hospital and community-based pharmacists who want to undertake a renal research study. For more information, click here: https://bit.ly/3KbRTwW 📣 Share this with your contacts and help spread the word about our new and exciting grant rounds. #KidneyResearch #GrantRounds #Funding